{"id":"nct:NCT05142722","kind":"trial","title":"Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies","authors":["NewAmsterdam Pharma"],"author_count":1,"year":2021,"published":"2021-12-03","venue":"ClinicalTrials.gov","cited_by":null,"doi":null,"arxiv_id":null,"nct_id":"NCT05142722","source_url":"https://clinicaltrials.gov/study/NCT05142722","archive_url":"https://space-kitty.com/papers/nct:NCT05142722","updated":"2025-09-19","pmid":null,"pmcid":null,"openalex_id":null,"pdf_url":null,"abstract":"This study will be a placebo-controlled, double-blind, randomized, phase 3 study in participants with underlying heterozygous familial hypercholesterolemia (HeFH) and/or ASCVD to evaluate the efficacy, safety, and tolerability of obicetrapib as an adjunct to diet and maximally tolerated lipid-lowering therapy","abstract_license":"ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters","license":"ClinicalTrials.gov terms (attribution, processing date, modifications noted)","is_open_access":true,"peer_reviewed":null,"categories":["Dyslipidemias","High Cholesterol","Hypercholesterolemia","Familial Hypercholesterolemia","Atherosclerotic Cardiovascular Disease"],"details":{"acronym":"BROADWAY","status":"COMPLETED","phase":"PHASE3","study_type":"INTERVENTIONAL","enrollment":2530,"sponsor":"NewAmsterdam Pharma","conditions":["Dyslipidemias","High Cholesterol","Hypercholesterolemia","Familial Hypercholesterolemia","Atherosclerotic Cardiovascular Disease"],"interventions":["DRUG: Placebo","DRUG: Obicetrapib"],"start_date":"2021-12-15","start_date_type":"ACTUAL","primary_completion_date":"2024-09-26","has_results":true,"data_source":"ClinicalTrials.gov","data_processed":"2026-10-29T09:00:05","modifications":"selected fields only; whitespace normalized; brief summary truncated to 2,000 characters"},"provenance":"clinicaltrials","attribution":"Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.","topics":[{"slug":"cardiovascular-innovation","name":"Cardiovascular Therapeutics","domain_slug":"medicine"}],"cited_in_dossiers":[]}